News Focus
News Focus
icon url

justdafactss

02/01/22 8:15 PM

#202242 RE: Rockleo #202240

Heres another reality- Without NP fanning the fantasy flames to shareholders, shareholders have to fan the fantasy flames to themselves.

Market will clobber that strategy worse than NP doing the touting.
icon url

theswordman

02/01/22 8:16 PM

#202243 RE: Rockleo #202240

Lots better than its been in YEARS. Still afraid of the 1-2 apples in the barrel

Hope the blue sky is not calm before the storm

great article in Nature today about LH

https://www.nature.com/articles/s41590-021-01104-y#Abs1
icon url

HyGro

02/01/22 10:41 PM

#202246 RE: Rockleo #202240

"superiority over Standard Of Care..in EVERY trial it has participated in." Not true. CoV failed to even show superiority to saline solution -- failed the CD10, CD12 and the Long CoV ("directional" results). HIV combo results are not as good as Gilead's capsid inhibitor (LL 81% vs 81-95% efficacy). Then NASH 305 mg had fat reduction (MDFF) of 16-20% when Madrigal's data was 48% for ~similar time period. GvHD -- Cytodyn gave up.

mTNBC analysis can't be compared the way CyDy did -- combing naive trial patients and heavily treated R/R patients -- can't compare to Trovaldy's super heavily treated R/R. It got the SEC/DOJ investigating the invalid comparison.

So bottomline. LL doesn't show commercial superiority in any indication.